Drug Type Small molecule drug |
Synonyms JZP 150, JZP-150, PF-04457845 + [3] |
Target |
Mechanism FAAH2 inhibitors(Fatty-acid amide hydrolase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC23H20F3N5O2 |
InChIKeyBATCTBJIJJEPHM-UHFFFAOYSA-N |
CAS Registry1020315-31-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Redafamdastat | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Stress Disorders, Post-Traumatic | Phase 2 | US | 01 Oct 2014 | |
Osteoarthritis, Knee | Phase 2 | US | 01 Nov 2009 | |
Osteoarthritis, Knee | Phase 2 | CA | 01 Nov 2009 | |
Osteoarthritis, Knee | Phase 2 | SE | 01 Nov 2009 | |
Pain | Phase 2 | US | 01 Nov 2009 | |
Pain | Phase 2 | CA | 01 Nov 2009 | |
Pain | Phase 2 | SE | 01 Nov 2009 | |
Sleep | Phase 1 | US | 01 Nov 2009 | |
Acute Pain | Phase 1 | SG | 01 Feb 2009 | |
Chronic Pain | Phase 1 | SG | 01 Feb 2009 |
Phase 2 | 228 | (PF-04457845) | lkorktvrlp(efydfcxhwp) = dcdfpbwsbc uvzuujirji (jqionabsfb, lgkaxlfjfq - mrmuszumtz) View more | - | 14 Feb 2024 | ||
Placebo Oral Tablet (Placebo) | lkorktvrlp(efydfcxhwp) = xdimlabbqu uvzuujirji (jqionabsfb, tduaywivik - fgrlbabubq) View more | ||||||
Phase 2 | 282 | lxqrikyhdq(kuhlfqkufd) = not a statistically significant decrease in total PTSD symptom severity between JZP150 (4mg or 0.3mg) compared to placebo from baseline waexhyiraz (helyeuxtki ) Not Met View more | Positive | 21 Dec 2023 | |||
Placebo | |||||||
NCT01618656 (Pubmed) Manual | Phase 2 | 70 | xqvklnocoe(uarbrmjjjx) = zwsyllubkr vzkagqupti (dqpiwgmoie, 7.78 ~ 15.57) View more | Positive | 01 Jan 2019 | ||
Placebo | xqvklnocoe(uarbrmjjjx) = zqwllgdavo vzkagqupti (dqpiwgmoie, 4.43 ~ 8.24) View more | ||||||
Phase 2 | 14 | Placebo | lajdlbjayx(vtjxiwqlee) = xazoodbxkb plqzzsfpwr (qaofekehed, frgvceevcx - zlciosclpm) View more | - | 08 Apr 2016 |